Kohei shitara
@KoheiShitara
Followers
2,281
Following
370
Media
17
Statuses
259
Medical oncologist at National Cancer Center Hospital East, Japan #gicancers #gastriccancer #colorectalcancer
Joined April 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
متعب الحربي
• 256684 Tweets
نيوكاسل
• 197180 Tweets
Happy New Month
• 106290 Tweets
#光る君へ
• 92099 Tweets
للهلال
• 80493 Tweets
الوليد بن طلال
• 72911 Tweets
BIGBANG
• 69224 Tweets
#ブラックペアン
• 43581 Tweets
#متعب_هلالي
• 36478 Tweets
やす子さん
• 30027 Tweets
India Will Become A Vishwaguru
• 28511 Tweets
プロジェクトKV
• 25946 Tweets
ブルアカ
• 24355 Tweets
やす子ちゃん
• 24190 Tweets
ライオンズ
• 21654 Tweets
#kpssönlisans
• 19419 Tweets
Piastri
• 18660 Tweets
海ちゃん
• 18423 Tweets
誰ソ彼ホテル
• 16432 Tweets
ابو خالد
• 15113 Tweets
ランニングホームラン
• 13082 Tweets
コールド
• 12543 Tweets
渡海先生
• 12385 Tweets
wrwrd
• 10464 Tweets
SPOTLIGHT study of
#Zolbetuximab
was just published in
@TheLancet
. Achievement by global collaboration to establish new treatment option for
#gastriccancer
.
@ILSONDavid
@mdmanishshah
@FlorianLordick
@KlempnerSam
@AstellasUS
@OncoAlert
@ASCO
@myESMO
4
60
184
Zolbetuximab plus FOLFOX improved PFS and OS in patients with claudin 18.2 positive gastric/GEJ cancer in the SPOTLIGHT study. This is great news for us and our patients. Please stay tune for the detail. .
.
#stomachcancer
@OncoAlert
@myESMO
@ASCO
5
52
181
KEYNOTE-585 is published
@TheLancetOncol
as presented at
#ESMO24
. Pembro+chemo improved pathCR of
#gastriccancer
but EFS was not statistically significant. MSI-H is distinguished population. Full results of Matterhorn awaited.
@OncoAlert
@myESMO
@ASCO
9
38
153
Proud to report updated CM649 results in
@Nature
with
@YJanjigianMD
and team. 2y OS 31% is the landmark of firstline for gastric cancer. Great achievement with study team
@bmsnews
and patients.
#GastricCancer
#immunotherapy
@OncoAlert
@VJOncology
@ASCO
9
51
147
Now published in the Nature Immunology. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade. Prospective study will be started to confirm the findings.
#GastricCancer
#immunotherapy
.
2
45
144
Great honor to share SPOTLIGHT of zolbetuximab in
#GI23
on global collaboration
@ILSONDavid
@mdmanishshah
@FlorianLordick
@KlempnerSam
@AstellasUS
.Thank you to all investigators, patients, family and team. New treatment for gastric
#cancer
!
@OncoAlert
@ASCO
@myESMO
@YJanjigianMD
Practice-changing research from
#GI23
: Zolbetuximab + mFOLFOX6 meets primary endpoint in SPOTLIGHT trial, improves PFS, OS in pts w/ CLDN18.2+, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ cancer:
#ASCODailyNews
#gicsm
#esocsm
0
37
89
1
24
139
Adjuvant Nivolumab plus chemo did not improve DFS after D2 gastrectomy in Asian ATTRACTION-5 trial. Ongoing perioperative studies are awaited (KN585 and Matterhorn).
#stomachcancer
@OncoAlert
@myESMO
@ASCO
4
32
122
Pleased to share PAGA guideline for
#gastriccancer
. Really appreciate Asian & European experts
@LizzySmyth1
@tfleitask
@GPentheroudakis
@AndresC27622123
who joined the discussion. Thank you
@myESMO
and
@JSMO_official
for excellent support.
1
42
117
Trastuzumab deruxtecan is now approved for HER2 positive gastric cancer by
@US_FDA
by our DESTINY-Gastric01 trial. This is great news for us and patients! Further studies are ongoing now! Lets’ keep research and collaborations.
#GI21
#HER2
#GastricCancer
3
23
111
Zolbetuximab plus chemo is approved in Japan for patients with claudin 18.2 positive gastric cancer. New treatment option for our patients with
#stomachcancer
! Approval pending in other countries.
@US_FDA
@AstellasUS
@ASCO
@myESMO
@OncoAlert
2
30
112
My pleasure to share review article of biomarker targeted therapies for gastric cancer on
@NatRevClinOncol
with Dr.
@YJanjigianMD
@FlorianLordick
. . Looking forward to adding more new agents in next several years.
#Gastriccancer
#Cancer
#biomarker
4
34
109
Happy to report ctDNA analysis of PARADIGM
@NatureMedicine
. Negative hyper selection enriched benefit of pani for CRC regardless of sidedness. Tumor location serve as surrogate for molecular type?
@NaturePortfolio
@myESMO
@ASCO
@TakedaOncology
@OncoAlert
4
38
107
Happy to report biomarkers in DESTINIY GC01
@NatureMedicine
. T-DXd response high if ctDNA+ while still activity observed in negative pts. Response regardless of KRAS, HER2, PIK3CA mt. ↓response in other RTKamp+. HER2 loss or topo1mt on PD.
@OncoAlert
3
27
106
Pleased to share our experience of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma
@myESMO
Gastrointestinal Oncology. 97.5% success rate using biopsy samples with median turn around time of 7 days.
1
25
109
Keynote 585 of perioperative pembrolizumab for
#gastriccancer
did not meet EFS endpoint despite higher pCR. Unfortunate but an important global study for localized gastroesophageal cancer. Stay tuned for full results
@OncoAlert
@myESMO
@ASCO
2
36
99
Happy to share the expanded analysis from Checkmate649 study which support chemo+Nivo as first line for GC/EGJ/EC. Although there is controversy of use in CPS low pts, further biomarker analysis is coming soon. Stay tune!
#GI21
@ASCO
@OncoAlert
2
12
92
Personal highlight at
#GI23
was sharing history of my unforgettable patient/friend who told me importance of ctDNA NGS (picture permitted by him and family). Thank you
@ASCO
for giving me the opportunity to join the session.
@OncoAlert
@myESMO
#cancer
#EGFR
4
5
88
Suggesting synergy between anti-HER2 and PD1!! Higher N of pts on treatment (40.6% vs 28.5%) in 264 pts in efficacy population and 433 safety population (58.5 vs 48.1%) suggest better PFS (and finally OS). Let's hopefully wait.
@YJanjigianMD
@SteveMaronMD
#ASCO21
#OncoAlert
Ph 3 KEYNOTE-811: Chemo + Trast + Pembro vs Chemo + Trast + Placebo for HER2 +ve gastric/GEJ cancer
⬆️ORR: 74% vs 51%, P = 0.00006
❗️Practice changing study
🤔Survival data needed
🤔What if PD-L1 negative?
#ASCO21
6
37
100
0
15
57
Pleased to share a review article of CLDN18.2 targeted therapy based on Japan and China collaboration. More and more data coming.
#stomachcancer
@nature
@NaturePortfolio
In a new Review, Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen & Kohei Shitara discuss Claudin 18.2 as a novel target for cancer therapy:
0
28
100
4
15
82
Happy to report part of ctDNA analysis from PARADIGM at
#GI23
which was previously presented at plenary session of ASCO23. Is sidedness just a surrogate for gene alterations? Need Validation.
@ASCO
@myESMO
@OncoAlert
0
19
79
Reporting association between whole-transcriptome sequencing and IHC. Reasonable concordance regarding HER2 and CLDN18.2 but not 100%. Need further analysis to clarify.
@OncoAlert
#stomachcancer
0
19
68
My great honor to be selected one of the list for
#HighlyCited
2023. This is based on the collaboration of our international colleagues and patients who contributed to the research.
@clarivate
@NccriOfficial
2
1
68
We are pleased to report results from phase 2 of trifluridine/tipiracil and ramucirumab for gastric cancer. DCR/ORR was 85%/9% at 2ndline and 77%/16% at 3rdline. Efficacies seems to be enhanced after PD1 blockade. .
#gastriccancer
#ramucirumab
4
25
64
Happy to publish the paper
@ESMO_Open
showing no prognostic impact of CLDN18.2 during standard chemotherapy or immunotherapy for GC/GEJ. Relatively low CPS>5 proportion in CLDN18.2+ population
@myESMO
@ASCO
@OncoAlert
Timely paper on CLDN18.2 in GC/GEJ from
@KoheiShitara
and team in
@myESMO
@ESMO_Open
May help contextualize trial data at
#GI23
@ASCO
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced GC/GEJ
0
24
59
3
10
66
Happy to share review of zolbetuximab for
#gastriccancer
. Regulatory approval still awaited.
0
9
66
Great honor to receive award at
#JSMO2023
for REVERCE study published
@Annals_Oncology
in 2019. Appreciate support by all investigators and patients/family. REVERCE2 (NCT04117945)
@GIcancerDoc
and PARERE (NCT04787341)
@ChiaraCrem1
are ongoing.
#ColorectalCancer
@ASCO
@myESMO
【ANNNONC賞 受賞講演】
◆日時：3/17（金）13:35～
◆会場：マリンメッセA館第一会場
栄えある2023年度のAnnals of Oncology賞の受賞者は、
（ﾀﾞﾗﾗﾗﾗﾗﾗﾗﾗﾗﾗ....）設楽紘平先生です！
受賞講演がございますので、ぜひご聴講ください。
設楽先生、おめでとうございます。
#JSMO2023
0
5
20
7
2
63
Dinner with NCCHE gastric team including oncologists, surgeons and pharmacists. Happy to have several visiting doctors from various countries. We are committed to patient care and future treatment development!
#stomachcancer
1
3
64
Another interesting observation was CLDN change between old archival vs baseline tumors in ILUSTRO and Japanese phase1 suggesting 40% pts with CLDN reduction during chemotherapy. Warrant further evaluation in chemo+PD1 or chemo+Zolbe treated pts.
Happy to report our analysis of CLDN18.2 expression globally! Important for those who will receive CLDN18.2 targeted Rx for gastric and gastroesophageal junction cancers!
Zolbetuximab is already approved in Japan! Hopefully we'll have access soon!
4
10
39
1
14
63
2nd P3 GLOW of Zolbetuximab also improved PFS and OS of patients with claudin 18.2+GC (CapeOX combo and different country distribution/more Chinese centers vs. SPOTLIGHT). Confirming Zolbetuximab efficacy!
#stomachcancer
@OncoAlert
@myESMO
@ASCO
1
22
62
Our Immunology TR department published new article in
@Cancer_Cell
cell showing MYC+ or liver metastasis augment PD1+ Treg cells with abundant lactic acid which result in resistant to PD1 blockade. MCT1 could be target
@OncoAlert
#immunotherapy
1
14
55
KEYNOTE-062 of pembrolizumab 1stline is published. Pleasure to join this global study. It suggested importance of patients enrichment when we use pembro mono upfront. Happy to discuss more after presentation of CheckMate649.
#gastriccancer
#gicancer
#pembrolizumab
#pd1
KEYNOTE-062 trial in loc adv gastric/GE jxn cancer shows 1st line pembrolizumab is non-inf to chemo w greater tx effect in pts w/MSI-H or high PD-L1 expression (CPS >10) & no meaningful benefit of pembro+chemo observed
@KoheiShitara
#GICSM
#VisualAbstract
11
46
88
1
16
52
Updated results of anti-PD1 plus regorafenib or lenvatinib for gastric cancer. Efficacy observed regardless of liver mets despite more immune-suppressive TME. Anti-PD1 mono was less effective for liver met.
@OncoAlert
@CCR_AACR
# gastriccancer
0
15
49
Our great pleasure to invite
@YJanjigianMD
and Dr.Wainberg to
#JSMO2023
and discuss
#stomachcancer
. Still we need more resarch to improve patients outcomes. Let's keep global collaboration!
@JSMO_official
@myESMO
@ASCO
Many improvements in
#gastric
cancer therapies from 2017 to 2023. Great to be back in Japan 🇯🇵 with
@KoheiShitara
at Japanese Society of Medical Oncology meeting. Looking forward to many more years of productive collaborations between our groups.
@MSKCancerCenter
3
7
137
2
8
48
ENHERTU/Trastuzumab deruxtecan Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer. Good to have more treatment options !
#stomachcancer
#FDA
4
10
43
Phase 1 trial of HSP90-inhibitor plus nivolumab for solid tumors. Objective response in 4 MSS CRC and 1 leiomyosarcoma. No response in 8 GC patients after anti-PD1. More work needed
#immunotherapy
#colorecalcancer
#gastriccancer
0
11
44
Impressive CAR-T results for CLDN18.2+tumors suggesting CLDN18.2 (+ CLDN6) as suitable target. Remaining CLDN+ cells after 1 infusion support repeated infusions or combinations. Many CLDN targeting treatments are investigated
@NatureMedicine
@OncoAlert
@myESMO
#immunotherapy
1
10
42
CheckMate649 trial will change standard care. Great honour to be the part of study. Congratulations to global team! appreciate all participants
#gastriccancer
#immunotherapy
@YJanjigianMD
0
7
41
Congratulations!
@YJanjigianMD
and all investigators. 23% ORR difference is larger than CM649 and single agents anti-PD1. Suggesting synergism between anti-HER2 and PD1. PFS and OS awaited.
Celebrating with my amazing research team! We changed SOC again
@sloan_kettering
Twice in one month.
#gastriccancer
@RWilliams_MSK
@RyanMoyMDPhD
@FDAOncology
approval
12
14
186
1
4
41
This is great achievement to change standard! Congratulations
@yjanjigianMD
,all investigators and BMSteam. Appreciate all patients who participated. Please stay tune on further update and Ipi Nivo arm.
#ASCO21
＃Oncoarert
#gastriccancer
#immunotherapy
＠bmsnews ＠ScienteAtBMS
Checkmate 649 published!
@sloan_kettering
✅
@KoheiShitara
#ASCO21
@ASCO
Leading Phase III studies is fun! Thank you to all the patients and caregivers, to my amazing colleagues and
@bmsnews
@ScienceAtBMS
24
109
352
2
11
40
Happy to share TMB analysis from KEYNOTE-061 with pembrolizumab for gastric cancer.
Suggesting predictive value of TMB in MSS pts. No clear relationship between TCGA subgroup (EBV/CIN/GS)and Pembro response.
#OncoAlert
@OncoAlert
1
8
39
It is our pleasure to report the results from Phase 2 of lenvatinib plus pembrolizumab for gastric cancer
1
14
39
RegoNivo for
#colorectalcancer
showed favorable outcomes in tumor with enriched CAF, EMT or Treg and M2 fraction. Considering lack of benefit in liver mets additonal resarch/treatment must be needed
@OncoAlert
@JITC
@sitcancer
0
5
36
Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.
#stomachcancer
@OncoAlert
1
7
36
Happy to share our experience with Nivolumab+ 1stline Chemo in Japan.
#stomachcancer
#immunotherapy
@OncoAlert
@myESMO
0
5
34
Excellent review for role of ERBB signalling and anti-tumor immunity by Dr Nishikawa and his team at our Immunology department. Combination should be the key to improve outcomes.
#EGFR
#HER2
#immunotherapy
0
6
31
RegoNivo for
#colorectalcancer
showed favorable outcomes in tumor with enriched CAF, EMT or Treg and M2 fraction. Considering lack of benefit in liver mets additonal resarch/treatment must be needed
@OncoAlert
@JITC
@sitcancer
New
#JITC
article: Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
@KoheiShitara
0
10
31
2
5
29
Now published in ESMO open. Among gastric cancer patients receiving taxanes plus ramucirumab (n=149), ORR (60.6 vs 20.0%) and PFS (4.8 vs 3.4 ms, HR=0.56) were significantly better in the anti PD-1-exposed compared with the antiPD-1-naïve.
0
8
28
Great news! Thank you all participants and family. It is up to guideline committees and physician to decide indication. I would test CPS. A lot of things needed for biomarkers or combinations. Continue global collaborations!
#gastriccancer
#immunotherapy
@YJanjigianMD
@OncoAlert
Excited to share the news!! Nivolumab FDA approved in 1st Line gastric cancer! Not restricted by CPS. Thankful to all our pts who participated in CM649.
@KoheiShitara
@sloan_kettering
@OncoAlert
4
49
204
2
3
26
Review for antibody–drug conjugates to treat gastric cancer
1
8
26
Great achievement by
@YJanjigianMD
and team. +23% ORR apparently suggests synergy between anti-HER2 and PD1 (ORR Pembro mono 10% in GC). Warrants further research for other targets (FGFR, EGFR, CLDN etc.)
@OncoAlert
@Nature
3 years from the phase II abstract
@OncoAlert
@ASCO
#GI19
to publication of interim Phase III. Thank you to collaborators
@KoheiShitara
@TaberneroJosep
&
@mvicaracal
@Nature
for easy pub process.
12
69
207
1
3
24
Case report of EGFR-amplified gastric cancer treated with cetuximab and summary of ctDNA from 148 patients. This and recent Gut paper by
@LizzySmyth1
suggest importance of targeting EGFR
@DocCatenacci
@SteveMaronMD
@KlempnerSam
@YJanjigianMD
2
11
26
Really appreciate patients and family who had joined the clinical trials. This advance is based on such significant contributions.
@AstellasUS
@OncoAlert
@ASCO
@myESMO
0
0
24
This was fantastic experience at
@sloan_kettering
. It was also my great pleasure to invite
@YJanjigianMD
to Japan.
Lets keep global collaboration and friendships!
@KoheiShitara
visit to
@sloan_kettering
2 years ago. The world 🌎 felt so small and well connected. Collaborations and ideas came so naturally—including a positive global Phase 3 CM649 study. These friendships and global connections are key!
1
7
78
1
3
21
Congratulations
@YJanjigianMD
@JeeyunM
and team to show initial encouraging efficacy of T-DXd and Cape combination. Exploraty analysis from GC01 may also support combo with IO. Looking forward to other cohorts in GC03 study
#GI21
@ASCO
@OncoAlert
The next chapter in
#her2positive
EG cancer. The RP2D dose T-DXd 6.4 mg/kg + Cap 1000 mg/m2 BID. 43% ORR in Chemo and traz refractory disease. Up next 1st line TDXd/cape/pembro
@ASCO
@OncoAlert
@JeeyunM
@sloan_kettering
@YJanjigianMD
1
27
116
0
4
20
RHOA Y42 mutations in gastric cancer may enable Treg cell accumulation
1
4
20
@DocCatenacci
Great discussion! Agree with that our results are based on 3rd or later pts. Most pts were enrolled into DESTINY GC01 with HER2+in archival tissue. We may present the subgroup HER2+ before and after trastuzumab. ctDNA results will be shared (HER2+ vs HER2-). Please stay tune.
2
4
17
@LizzySmyth1
@OncoAlert
@JCO_ASCO
@sundar__raghav
@VJOncology
@myESMO
No doubt pts with low CPS has less benefit. Hopefully ongoing studies LEAP-015, Attraction-6, chemo+RegoNivo or other agents (zolbetuximab and bemarituzumab) will improve outcomes of these patients
1
7
15
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
#GI24
#stcsm
#esocsm
#GEJcancer
#oncology
#immunotherapy
1
1
3
0
1
15
@DocCatenacci
@ahmadalhader
@pashtoonkasi
@OncoAlert
@tmprowell
@marklewismd
@DrSGraff
@ILSONDavid
@NicoleKuderer
@BenWestphalen
@oncologician
From my experience, there is no clear relationship between ILD and previous anti-PD1 exposure (1/3 pts in DESTINY GC01 had previously received it). Breast cancer trial showed similar incidence of ILD (10%) with TDXd+Nivo. Nevertheless, I agree with that we need more data.
1
1
13
Proud to be named a Highly Cited Researcher 2022 by
@ClarivateAG
. See the full list
#HighlyCited2022
2
1
12
@pashtoonkasi
@OncoAlert
@DocCatenacci
@tmprowell
@marklewismd
@DrSGraff
@ILSONDavid
@NicoleKuderer
@BenWestphalen
@oncologician
There seems to be at least two pattern including COP pattern and AIP pattern. COP is more common and well responded to steroid in my experience. More data is needed for AIP like ILD. I hope improvement of your patient
1
4
12
Great news !
$BMY announces positive Phase 3 trial results in first-line gastric and esophageal
#cancers
6
31
131
0
3
11
@pashtoonkasi
@DocCatenacci
@oncologician
@OncoAlert
@TheLancetOncol
@YJanjigianMD
@BenWestphalen
@marklewismd
@ILSONDavid
@mdmanishshah
@agrothey
@AnwaarSaeed3
@IntMedatIowa
These results were based on relatively selected population with good PS though we did not select patients by biomarker. Response was evaluated by each investigators but ct scans from all patients were reviewed during discussion for next study. Let’s see how it goes
0
1
11
@YJanjigianMD
@DocCatenacci
@AkiStoCAN
@BijoyTelivala
@sloan_kettering
@OncoAlert
@FDAOncology
@SteveMaronMD
I do not want to say that CPS is not reliable. We made this as primary endpoint based on rationale from CM032 with validated method. One pitfall of CPS5 is to miss some MSI-H patients.
2
2
10
Congratulations on excellent presentation!
@JeeyunM
Our pleasure to work for ASCO education book also. Lets keep collaboration.
#ASCO21
#OncoAlert
I enjoyed working with my colleagues epsecially with Dr. Shitara and Dr. Nakamura. This is a summary of biomarkers tested in GC, especially in Japan/Korea + what biomarkers can do to optimize patient's treatment. I think it will be an exciting time for GC.
0
7
32
0
0
10
It is my great pleasure to join AGITG annual scientific meeting!
Great Opening Keynote with Prof Kohei Shitara - a great start to the day!
#AGITGonline
#gicancer
0
2
4
1
0
9
@YJanjigianMD
@DocCatenacci
@AkiStoCAN
@BijoyTelivala
@sloan_kettering
@OncoAlert
@FDAOncology
@SteveMaronMD
Yes. We need to compare CPS by 22C3 and 28-8 to explain some difference in frequencies of CPS5 in CM649(-60%) and KN studies (30%-). Before that, I think it is better to use 28-8 when use Nivo at 1stline.
1
3
7
0
1
7
@pashtoonkasi
@FDAOncology
@YJanjigianMD
@ILSONDavid
@DocCatenacci
@OncoAlert
@NEJM
@GIcancerDoc
@DrKelseyKlute
@drallysonocean
@MPishvaian
@Dr_R_Kurzrock
@MayCho_MD
@CathyEngMD
@BenWestphalen
@GreatDebatesGI
Thank you. Phase 2 at 2ndline is ongoing at US and EU. I personally think results of DESTINY-GC01 worth discussion with any regulatory authority. Let’s wait see how it goes.
0
1
7
@KlempnerSam
@LizzySmyth1
@DocCatenacci
@SteveMaronMD
@YJanjigianMD
10ms CR suggest activity of combination in this aggressive population. Please share the outcomes after dual targets therapy in the future.
0
0
6
@YJanjigianMD
The results are disappointing but agree with that there is difference in treatment line, PS,etc. as shown in KN062, chemo free regimen may be more suitable for Asian pts.
0
0
4
@mdmanishshah
Agree that more data is needed. But this indicated older samples were stained better than samples just before study enrollment. Previous ESMO open data (3 of 5) and recent MDA data (9 of 22pts) also showed same trend. Interesting.
0
0
3
@DocCatenacci
@oncologician
@TumorBoardTues
@pashtoonkasi
Yes. We will also try to compare archival vs fresh in same patients, although sample size for this is small.
0
0
4
@antonyruggeri
@US_FDA
@YJanjigianMD
@DocCatenacci
@JoeChaoMD
@ILSONDavid
@pashtoonkasi
@agrothey
@GIcancerDoc
@CathyEngMD
Japanese approval is for 3rdline or later. Japanese guideline recommend it for 3rdline.
0
1
4
@KlempnerSam
@NEJM
@RonaYaeger
@AlexSpiraMDPhD
@oncoOuLungCA
@GIcancerDoc
@MGHCancerCenter
Great! Congratulations!!
0
0
3
@LizzySmyth1
@JAMAOnc
Not sure now. Gut paper may contradict the better outcome in Asia. MSI-H and CPS10 no diff. TMB may not be. More based on clinical factors?? Need such multifactorial analysis
1
0
3
@Thalcin
@TheLancetOncol
@OncoAlert
@myESMO
@ASCO
Thank you. MSI-H was detected in around 9%. pCR+37%, EFS HR 0.59 and OS HR 0.38
0
2
3
@FilippoPietran4
@jitcancer
@elena_elez
@KlempnerSam
@mgfakih
@JoeChaoMD
@lonardi_sara
@ChiaraCrem1
Congratulations! Our pleasure to join this analysis
1
0
3
0
0
3
@pashtoonkasi
@myESMO
@ESMO_Open
It is interesting that several reports showed same phenomenon. Previous resarch also suggested change of TME after taxane+RAM. let's wait for ongoing SEQUEL study.
1
3
3
@fernandbteich
@TheLancetOncol
@OncoAlert
@myESMO
@ASCO
No CPS5 cut off as same as KN859. Exploratory CPS10 group showed EFS HR 0.70
0
0
1
@fireflyann
@pashtoonkasi
@OncoAlert
@DocCatenacci
@tmprowell
@marklewismd
@DrSGraff
@ILSONDavid
@NicoleKuderer
@BenWestphalen
@oncologician
Pooled analysis did not show relationship between ILD and lung metastasis. Other lung comorbidities (COPD etc) may need careful watch
1
0
3
@LFerri123
Thank you. The trial was discussed before FLOT4 report, so the control arm of main cohort was kept as doublet. Of note, most pts had stomach primary and nearly 40% of pts had T4a or higher vs <13% in FLOT4 study. FLOT cohort results (N~200pts) will be presented at ASCO GI.
0
1
3
@DocCatenacci
claim of non-inferiority follow the initial plan but completely agree that CPS1 is at least mixed population with yin and yang curve.
0
1
3
@AravindSanjeev3
@DocCatenacci
@doctorC369
@LizzySmyth1
study/doublet chemo/ FLOT in selected pts. Tras not approved/reimbursed for localized disease.
0
0
2
@giammi107
@OncoAlert
@jitc
@sitcancer
Yes. Not always presence of M2 mean cold tumor. Hopefully we will report how multi kinase inhibitor target immune suppressive cells near future
1
0
2
0
0
1
@KatharineAtMSK
@ASCO
@OncoAlert
@myESMO
He passed away after treatment, but he always asked me to share his treatment course to others. When I reported this
#GI23
to his wife, she thanked me to taking them to SF with me.
0
0
2
@DrKelseyKlute
@JAMAOnc
Pts could be enrolled if they completed neo- or adj tx 6 months before as usual 1stline study. Detail was not reported. In forest plot, 74% of pts had no gastrectomy (thus w/o chemo before enroll) with HR 0.94.
0
0
2
@antonyruggeri
@PTarantinoMD
@JAMAOnc
@DFCI_BreastOnc
@stolaney1
@curijoey
@JavierCortesMD
@ErikaHamilton9
@FAndreMD
Same trend in GC but not large difference. ILD was 10% (Japan>Korea) in GC01 and 8% in GC02 (non Asia).
0
1
2